EURAP Outcomes for Seizure Control during Pregnancy: Useful and Encouraging Data
- 31 October 2006
- journal article
- editorial
- Published by SAGE Publications in Epilepsy Currents
- Vol. 6 (6), 186-188
- https://doi.org/10.1111/j.1535-7511.2006.00140.x
Abstract
Seizure Control and Treatment in Pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry EURAP Study Group Neurology 2006;66:354–360 Objective To analyze seizure control and treatment in pregnant women with epilepsy. Methods Seizure control and treatment were recorded prospectively in 1,956 pregnancies of 1,882 women with epilepsy participating in EURAP, an international antiepileptic drugs (AEDs) and pregnancy registry. Results Of all cases, 58.3% were seizure-free throughout pregnancy. Occurrence of any seizures was associated with localization-related epilepsy (OR, 2.5; 1.7 to 3.9) and polytherapy (OR, 9.0; 5.6 to 14.8) and for tonic–clonic seizures, with oxcarbazepine monotherapy (OR, 5.4; 1.6 to 17.1). Using first trimester as reference, seizure control remained unchanged throughout pregnancy in 63.6%, 92.7% of whom were seizure free during the entire pregnancy. For those with a change in seizure frequency, 17.3% had an increase and 15.9% a decrease. Seizures occurred during delivery in 60 pregnancies (3.5%), more commonly in women with seizures during pregnancy (OR, 4.8; 2.3 to 10.0). There were 36 cases of status epilepticus (12 convulsive), which resulted in stillbirth in one case but no cases of miscarriage or maternal mortality. AED treatment remained unchanged in 62.7% of the pregnancies. The number or dosage of AEDs were more often increased in pregnancies with seizures (OR, 3.6; 2.8 to 4.7) and with monotherapy with lamotrigine (OR, 3.8; 2.1 to 6.9) or oxcarbazepine (OR, 3.7; 1.1 to 12.9). Conclusions The majority of patients with epilepsy maintain seizure control during pregnancy. The apparently higher risk of seizures among women treated with oxcarbazepine and the more frequent increases in drug load in the oxcarbazepine and lamotrigine cohorts prompts further studies on relationships with pharmacokinetic changes. Risks associated with status epilepticus appear to be lower than previously reported.Keywords
This publication has 9 references indexed in Scilit:
- In utero antiepileptic drug exposureNeurology, 2006
- Seizure control and treatment in pregnancyNeurology, 2006
- Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy RegisterJournal of Neurology, Neurosurgery & Psychiatry, 2006
- The prevalence of stillbirths: a systematic reviewReproductive Health, 2006
- Individual changes in lamotrigine plasma concentrations during pregnancyEpilepsy Research, 2005
- Safety of the newer antiepileptic drug oxcarbazepine during pregnancyCurrent Medical Research and Opinion, 2005
- Gestation-induced changes in lamotrigine pharmacokinetics: A monotherapy studyNeurology, 2004
- The impact of pregnancy and childbirth on the metabolism of lamotrigineNeurology, 2004
- Antiepileptic drug pharmacokinetics during pregnancy and lactationNeurology, 2003